StockData

AIM ImmunoTech vs aTYR PHARMA

AIM and ATYR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AIM and ATYR compare

aTYR PHARMA is the larger company, worth 3.8 times as much as AIM ImmunoTech ($17.0M against $4.5M).

aTYR PHARMA scores higher on the StockData Score (6 against 2 for AIM ImmunoTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAIMATYR
Size and price
Market cap$4.5M$17.0M
Share price$0.148$6.77
Change, 1 year−90.6%−78.6%
Change, 5 years−99.9%−97.9%
Beta (5Y)0.84–
Employees–58
StockData Score
Total score26 (better)
Valuation score11
Growth score00
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/S47.6×–
P/B0.6×0.5× (better)
FCF yield–−258%
Growth
Revenue growth (TTM)−21.5%–
Revenue growth, 5Y average−11.6% (better)−55.1%
Profitability
Operating margin−11724%–
Net margin−15021%–
Return on equity−2382%−93.4% (better)
Financial health
Debt / equity0.47 (better)0.00
Interest coverage−9.8×–
Current ratio2.113.05 (better)
Altman Z-score−51.04−17.13 (better)
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions3.8%–
Held by insiders12.8%99.6%
Insider net buying, 12 months$33.9K$43.7K (better)
Short interest, % of float3.8%3302%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.